Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]    
Revenues $ 6,301 $ 3,756
Cost of Revenues 1,609 1,076
Gross Profit 4,692 2,680
Operating Expenses    
Research and development 3,893 1,231
Sales and marketing 3,043 1,726
General and administrative 13,660 14,149
Acquisition-related costs 1,277 108
Impairment of goodwill 636
Amortization of intangibles 3,629 3,232
Total Operating Expenses 25,502 21,082
Loss from Operations (20,810) (18,402)
Other Income (Expense)    
Interest expense, net (2,277) (1,241)
Loss on exchange of debt for equity (294)
Change in fair value of derivative liability 48
Gain on the sale of Sysorex Arabia 23
Provision for valuation allowance on related party loan - held for sale (10,627)
Other income/(expense) (558) (211)
Total Other Income (Expense) (13,756) (1,381)
Net Loss from Continuing Operations, before tax (34,566) (19,783)
Income tax benefit 584
Net Loss from Continuing Operations (33,982) (19,783)
Loss from Discontinued Operations, Net of Tax (4,778)
Net Loss (33,982) (24,561)
Net Income/(Loss) Attributable to Non-controlling Interest 9 11
Net Loss Attributable to Stockholders of Inpixon (33,991) (24,572)
Deemed dividend to preferred stockholders (6,407)
Deemed dividend for triggering of warrant down round feature (1,250) (13,645)
Net Loss Attributable to Common Stockholders $ (35,241) $ (44,624)
Net Loss Per Basic and Diluted Common Share    
Loss from continuing operations $ (47.52) $ (2,322.30)
Loss from discontinued operations (278.47)
Net Loss Per Share - Basic and Diluted $ (47.52) $ (2,600.77)
Weighted Average Shares Outstanding    
Basic and Diluted 741,530 17,158